Condition
B-cell Lymphoid Malignancies
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Completed2
Withdrawn2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05263739Phase 1WithdrawnPrimary
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
NCT05822843Phase 1CompletedPrimary
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
NCT02569476Phase 1CompletedPrimary
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
NCT04684979Phase 2WithdrawnPrimary
Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies
Showing all 4 trials